Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-cash Items: 2015-2023

  • Theravance Biopharma's Non-cash Items rose 10.84% to $859,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $859,000, marking a year-over-year increase of 10.84%. This contributed to the annual value of $859,000 for FY2023, which is 10.84% up from last year.
  • According to the latest figures from Q4 2023, Theravance Biopharma's Non-cash Items is $859,000, which was up 10.84% from $775,000 recorded in Q4 2022.
  • Theravance Biopharma's 5-year Non-cash Items high stood at $8.5 million for Q4 2019, and its period low was $775,000 during Q4 2022.
  • For the 3-year period, Theravance Biopharma's Non-cash Items averaged around $901,333, with its median value being $859,000 (2023).
  • As far as peak fluctuations go, Theravance Biopharma's Non-cash Items skyrocketed by 66.67% in 2019, and later crashed by 85.88% in 2020.
  • Theravance Biopharma's Non-cash Items (Quarterly) stood at $8.5 million in 2019, then tumbled by 85.88% to $1.2 million in 2020, then declined by 10.83% to $1.1 million in 2021, then declined by 27.57% to $775,000 in 2022, then increased by 10.84% to $859,000 in 2023.
  • Its Non-cash Items was $859,000 in Q4 2023, compared to $775,000 in Q4 2022 and $1.1 million in Q4 2021.